How proteomics can assist in the detection and avoidance of adverse drug reactions

Transfusion Medicine and Hemotherapy

Volumn 33, Issue 1, 2006, Pages 97-105

  Wilkins, Marc R ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adverse drug reactions; Biomarkers; Immunoproteomics; Proteomics

Indexed keywords

CARCINOGEN; NEVIRAPINE; NITROSOMORPHOLINE; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; PENICILLAMINE; PROTEIN;

DISEASE MODEL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG TOXICITY; DRUG WITHDRAWAL; EXPERIMENTAL ANIMAL; HOSPITAL ADMISSION; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TIME; TWO DIMENSIONAL GEL ELECTROPHORESIS; WITHDRAWAL SYNDROME;

EID: 33644528448     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090205     Document Type: Review

References (58)

1. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, Williams KL: Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1995;13:19-50.
2. Gooley AA, Packer NH: The importance of protein co- and post-translational modifications in proteome projects; in Wilkins MR, Williams KL, Appel RD, Hochstrasser DF (eds): Proteome Research: New Frontiers in Functional Genomics. Heidelberg, Springer, 1997, pp 65-91.
3. Ballif BA, Villen J, Beausoleil SA, Schwartz D, Gygi SP: Phosphoproteomic analysis of the developing mouse brain. Mol Cell Proteomics 2004;3:1093-101.
4. Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, Schultz J, Rick JM, Michon AM, Cruciat CM, Remor M, Hofert C, Schelder M, Brajenovic M, Ruffner H, Merino A, Klein K, Hudak M, Dickson D, Rudi T, Gnau V, Bauch A, Bastuck S, Huhse B, Leutwein C, Heurtier MA, Copley RR, Edelmann A, Querfurth E, Rybin V, Drewes G, Raida M, Bouwmeester T, Bork P, Seraphin B, Kuster B, Neubauer G, Superti-Furga G: Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002 415:141-7.
5. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A, Koeppen S, Timm J, Mintzlaff S, Abraham C, Bock N, Kietzmann S, Goedde A, Toksoz E, Droege A, Krobitsch S, Korn B, Birchmeier W, Lehrach H, Wanker EE: A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005;122:957-68.
6. Bork P, Serrano L: Towards cellular systems in 4D. Cell 2005;121:507-9.
7. Pandey A, Mann M: Proteomics to study genes and genomes. Nature 2000;405:837-46.
8. O'Farrell PH: High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975;250:4007-21.
9. Klose J: Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 1975;26:231-43.
10. Petricoin EF, Liotta LA: SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:24-30.
11. Tao WA, Aebersold R: Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr Opin Biotechnol 2003;14:110-8.
12. Jensen ON: Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol 2004;8:33-41.
13. Dziembowski A, Seraphin B: Recent developments in the analysis of protein complexes. FEBS Lett 2004;556:1-6.
14. Gorg A, Weiss W, Dunn MJ: Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004;4:3665-85.
15. Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF, Mocarelli P: Renal cell carcinoma and normal kidney protein expression. Electrophoresis 1997;18:599-604.
16. Klose J, Nock C, Herrmann M, Stuhler K, Marcus K, Bluggel M, Krause E, Schalkwyk LC, Rastan S, Brown SD, Bussow K, Himmelbauer H, Lehrach H: Genetic analysis of the mouse brain proteome. Nat Genet 2002;30:385-93.
17. Neuhoff V, Stamm R, Eibl H: Clear background and highly sensitive protein staining with Coomassie Blue dyes in polyacrylamide gels: a systematic analysis. Electrophoresis 1985;6:427-448.
18. Unlu M, Morgan ME, Minden JS: Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997;18:2071-7.
19. Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C: Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci U S A 1993;90:5011-5.
20. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999;20:3551-67.
21. Traini M, Gooley AA, Ou K, Wilkins MR, Tonella L, Sanchez JC, Hochstrasser DF, Williams KL: Towards an automated approach for protein identification in proteome projects. Electrophoresis 1998;19:1941-9.
22. Yates JR 3rd, Eng JK, McCormack AL: Mining genomes: correlating tandem mass spectra of modified and unmodified peptides to sequences in nucleotide databases. Anal Chem 1995;67:3202-10.
23. Mann M, Wilm M: Error-tolerant identification of peptides in sequence databases by peptide sequence tags. Anal Chem 1994;66:4390-9.
24. Delahunty C, Yates JR 3rd: Protein identification using 2D-LC-MS/MS. Methods 2005;35:248-55.
25. Shen Y, Kim J, Strittmatter EF, Jacobs JM, Camp DG Jr, Fang R, Tolie N, Moore RJ, Smith RD: Characterization of the human blood plasma proteome. Proteomics 2005;5:4034-45.
26. Yu LR, Conrads TP, Uo T, Kinoshita Y, Morrison RS, Lucas DA, Chan KC, Blonder J, Issaq HJ, Veenstra TD: Global analysis of the cortical neuron proteome. Mol Cell Proteomics 2004;3:896-907.
27. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R: () Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17:994-9.
28. 18O labeling: a tool for proteomics. Rapid Commun Mass Spectrom 2001;15:2456-65.
29. Krijgsveld J, Ketting RF, Mahmoudi T, Johansen J, Artal-Sanz M, Verrijzer CP, Plasterk RH, Heck AJ: Metabolic labeling of C. elegans and D. melanogaster for quantitative proteomics. Nat Biotechnol 2003;21:927-31.
30. Sebastiano R, Citterio A, Lapadula M, Righetti PG: A new deuterated alkylating agent for quantitative proteomics. Rapid Commun Mass Spectrom 2003;17:2380-6.
31. Liu H, Sadygov RG, Yates JR 3rd: A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193-201.
32. Belov L, Huang P, Barber N, Mulligan SP, Christopherson RI: Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 2003;3:2147-54.
33. Hutchens TW, Yip TT: New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom 1993;7:576-580.
34. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
35. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
36. Baggerly KA, Morris JS, Edmonson SR, Coombes KR: Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-9.
37. Caputo E, Moharram R, Martin BM: Methods for on-chip protein analysis. Anal Biochem 2003;321:116-24.
38. Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.
39. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205.
40. Wilkins MR: What do we want from proteomics in the detection and avoidance of adverse drug reactions. Toxicol Lett 2002;127:245-9.
41. Simpson DM, Beynon RJ, Robertson DH, Loughran MJ, Haywood S: Copper-associated liver disease: a proteomics study of copper challenge in a sheep model. Proteomics 2004;4:524-36.
42. Meneses-Lorente G, Guest PC, Lawrence J, Muniappa N, Knowles MR, Skynner HA, Salim K, Cristea I, Mortishire-Smith R, Gaskell SJ, Watt A: A proteomic investigation of drug-induced steatosis in rat liver. Chem Res Toxicol 2004;17:605-12.
43. Fountoulakis M, Berndt P, Boelsterli UA, Crameri F, Winter M, Albertini S, Suter L: Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis 2000;21:2148-61.
44. Man WJ, White IR, Bryant D, Bugelski P, Camilleri P, Cutler P, Heald G, Lord PG, Wood J, Kramer K: Protein expression analysis of drug-mediated hepatotoxicity in the Sprague-Dawley rat. Proteomics 2002;2:1577-85.
45. Kennedy S: Proteomic profiling from human samples: the body fluid alternative. Toxicol Lett 2001;120:379-84.
46. Amacher DE, Adler R, Herath A, Townsend RR: Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem 2005;51:1796-803.
47. Dare TO, Davies HA, Turton JA, Lomas L, Williams TC, York MJ: Application of surface-enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin-alpha: a biomarker of compound-induced skeletal muscle toxicity in the rat. Electrophoresis 2002;23:3241-51.
48. Uetrecht JP: Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr Drug Metab 2000;1:133-41.
49. Shenton JM, Chen J, Uetrecht JP: Animal models of idiosyncratic drug reactions. Chem Biol Interact 2004;150:53-70.
50. Klade CS: Proteomics approaches towards antigen discovery and vaccine development. Curr Opin Mol Ther 2002;4:216-23.
51. Haas G, Karaali G, Ebermayer K, Metzger WG, Lamer S, Zimny-Arndt U, Diescher S, Goebel UB, Vogt K, Roznowski AB, Wiedenmann BJ, Meyer TF, Aebischer T, Jungblut PR: Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2002;2:313-24.
52. Cui JW, Li WH, Li HY, Li AL, He K, Wang J, Wang HX, Li W, Kang LH, Yu M, Shen BF, Wang GJ, Zhang XM: Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 2005;4:1718-1724.
53. Hess JL, Blazer L, Romer T, Faber L, Buller RM, Boyle MD: Immunoproteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2005;815:65-75.
54. Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR: Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis 2003;24:757-70.
55. Fella K, Gluckmann M, Hellmann J, Karas M, Kramer PJ, Kroger M: Use of two-dimensional gel electrophoresis in predictive toxicology: identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis. Proteomics 2005;5:1914-27.
56. Yeom M, Shim I, Lee HJ, Hahm DH: Proteomic analysis of nicotine-associated protein expression in the striatum of repeated nicotine-treated rats. Biochem Biophys Res Commun 2005;326:321-8.
57. Kim SY, Chudapongse N, Lee SM, Levin MC, Oh JT, Park HJ, Ho IK: Proteomic analysis of phosphotyrosyl proteins in morphine-dependent rat brains. Brain Res Mol Brain Res 2005;133:58-70.
58. Mouledous L, Neasta J, Uttenweiler-Joseph S, Stella A, Matondo M, Corbani M, Monsarrat B, Meunier JC: Long-term morphine treatment enhances proteasome-dependent degradation of G beta in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylate cyclase sensitization. Mol Pharmacol 2005;68:467-76.